Health Minister J P Nadda takes review meeting of Department of Pharmaceuticals
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Department presents a detailed overview of the Pharma and MediTechsector and gives a detailed presentation on the activities of Department
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
This is the first peptide product approval from the USFDA received by Alembic Pharmaceuticals
First and only BTK inhibitor to demonstrate favourable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting
Augtyro is the only FDA-approved treatment option for NTRK-positive tumors studied in both TKI-naïve and TKI-pretreated patients across solid tumors
Nadda expressed his concern about growing incidence of Non-Communicable Diseases and the importance of awareness regarding healthy diet and lifestyle
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Subscribe To Our Newsletter & Stay Updated